ClinicalTrials.gg
Enrolling by invitationNCT06048926Updated Sep 21, 2023

Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma

An interventional study of Carrelizumab and Paclitaxel injection in Esophageal Squamous Cell Carcinoma, sponsored by The First Affiliated Hospital with Nanjing Medical University. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as enrolling by invitation.
  • Registered 7 months after the study started (first participant enrolled Jul 2022, registered Mar 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing camrelizumab in Esophageal Squamous Cell Carcinoma — 5 open to participants now, 7 under way, 2 of them phase 3. camrelizumab · Esophageal Squamous Cell Carcinoma.

Planned enrollment
17th of 20
30 · median 46
Started
2022
with 1 other
No phase
3 of 20
1 open now
Registered
16th of 20
by date
Lead sponsor
2 of 20
The First Affiliated Hospital with Nanjing Medical University

Among the 20 studies testing camrelizumab in Esophageal Squamous Cell Carcinoma, this one is the 17th largest by planned enrollment, is one of 2 that started in 2022, is one of 3 with no phase, and was the 16th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

5 of the 20 studies testing camrelizumab in Esophageal Squamous Cell Carcinoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing camrelizumab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study to evaluate the efficacy and safety of carrelizumab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy in the treatment of patients with inoperably advanced esophageal cancer, and to explore the relationship between PD-L1 expression and efficacy in tumor tissues. Experimental group: carrelizumab in combination with concurrent chemoradiotherapy PD-1: carrelizumab: 200 mg/3W Chemotherapy: Paclitaxel: 50 mg/m2/W Cisplatin: 25mg/m2/W Radiotherapy: 50.4 Gy / 28 f Chemotherapy drugs are used for 5 cycles, and carrelibizumab is used for up to 24 months until PD or is intolerable Control group: placebo-resistant in combination with chemoradiotherapy placebo: 200 mg/3 W Chemotherapy: Paclitaxel: 50 mg/m2/W Cisplatin: 25mg/m2/W Radiotherapy: 50.4 Gy / 28 f Chemotherapy drugs are used for 5 cycles, and carrelibizumab is used for up to 24 months until PD or is intolerable

Read the detailed description

Experimental group: carrelizumab in combination with concurrent chemoradiotherapy PD-1: carrelizumab: 200 mg/3W Chemotherapy: Paclitaxel: 50 mg/m2/W Cisplatin: 25mg/m2/W Radiotherapy: 50.4 Gy / 28 f Chemotherapy drugs are used for 5 cycles, and carrelibizumab is used for up to 24 months until PD or is intolerable Control group: placebo-resistant in combination with chemoradiotherapy placebo: 200 mg/3 W Chemotherapy: Paclitaxel: 50 mg/m2/W Cisplatin: 25mg/m2/W Radiotherapy: 50.4 Gy / 28 f Chemotherapy drugs are used for 5 cycles, and carrelibizumab is used for up to 24 months until PD or is intolerable

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma

Keywords

  • Carrelizumab
  • Concurrent chemoradiotherapy
  • Esophageal Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients voluntarily participate in this study and sign ;
  2. Age 18-75 years, including 18 and 75 years old, male or female;
  3. Patients with confirmed locally advanced esophageal squamous cell carcinoma with a clinical stage of stage II-IVa that is inoperably resectable (including unresectable, or has to surgery or refuses surgery) (according to the 8th edition AJCC stage, the pre-treatment clinical stage is: cT1N2-3M0, cT2-4bN0-3M0);
  4. the presence of measurable and/or non- that meet the definition of the Efficacy Evaluation Criteria for Solid Tumors (RECIST1.1);
  5. Have not received systemic antineoplastic therapy (including but not limited to systemic chemotherapy, molecularly targeted therapy, immunotherapy, biological therapy, topical therapy, and other therapies)
  6. : 0\~1 point
  7. Fresh or archived tumor tissue samples within 6 months (fresh samples preferred) must be provided for biomarker (such as ) analysis, the sample type is FFPE tumor tissue block or at least 5 unstained, 3-5 μm thick FFPE tumor tissue section, for subjects who cannot provide tissue samples that meet the above requirements, they can discuss with the sponsor to determine whether to enroll;
  8. Expected survival≥ 3 months;
  9. The function of vital organs meets the following requirements (no blood components and cell growth factors are allowed 2 weeks before starting screening tests):

    1. (ANC) ≥1.5×109/L;
    2. ≥ 100×109/L;
    3. ≥ 9g/dL;
    4. serum albumin≥ 2.8 g/dL;
    5. Total ≤ 1.5 × , , AST and/or AKP≤2.5 × ULN;
    6. Serum creatinine ≤1.5 × ULN or ≥ 60 mL/min (calculated according to the Cockcroft-Gault formula, see Annex II);
    7. (INR) and activated partial thromboplastin time (APTT) ≤1.5× ULN (can be screened for anticoagulation at a stable dose such as low molecular weight heparin or warfarin and INR within the expected therapeutic range of anticoagulants);
  10. Female subjects of should have a urine or serum pregnancy test within 72 hours prior to receiving the first study drug administration and demonstrate a negative testament,and be willing to use an effective method of during the trial period to 3 months after the last dose. For male participants whose partner is a woman of childbearing age, effective methods of contraception should be used during the trial and up to three months after the last dose

Exclusion criteria

Exclusion Criteria:

  1. history of surgery for esophageal cancer;
  2. history of previous fistula due to primary tumor invasion;
  3. a higher risk of gastrointestinal bleeding, esophageal fistula, or esophageal perforation;
  4. participants with poor nutritional status with a of less than 18.5 kg/m2 or a PG-SGA score of ≥9;
  5. have undergone major surgery or severe trauma within 4 weeks prior to the first use of the study drug;
  6. presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage;
  7. Have received or are currently receiving any of the following treatments:

    1. Anti- or anti-PD-L1 antibody therapy, chemotherapy, radiotherapy, targeted therapy;
    2. Have received any drug within 4 weeks prior to the first use of the investigational drug;
    3. Participants who require systemic therapy with (> 10 mg prednisone equivalent per day) or other within 2 weeks prior to the first study drug, except for local inflammation of the esophagus and for the prevention of allergies and nausea and vomiting. In other special circumstances, it is necessary to communicate with the sponsor. In the absence of active disease, inhaled or topical steroid replacement and adrenocorticosteroid replacement at a dose > a potent dose of 10 mg/day prednisone is allowed;
    4. Those who have received an antitumor vaccine or have received a within 4 weeks prior to the first dose of the study drug
  8. have any active autoimmune disease or history of autoimmune disease (eg, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary physitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism); Except vitiligo or patients with asthma/allergies of the same age who have recovered and do not require any intervention in adulthood; Patients with autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone and type I diabetes mellitus treated with stable doses of insulin may be included;
  9. a history of immunodeficiency, including a positive test, or other acquired or congenital immunodeficiency disorders, or a history of organ transplantation and bone marrow transplantation;
  10. Subjects with uncontrolled cardiac clinical symptoms or diseases, such as (1) heart failure with II and above, (2) unstable angina, (3) myocardial infarction within 1 year, (4) supraventricular or ventricular arrhythmias requiring clinical intervention;
  11. Severe infection (CTC AE> grade 2) within 4 weeks prior to the first use of the study drug, such as severe pneumonia, bacteremia, infection comorbidities, etc. requiring hospitalization; Baseline chest imaging suggests active lung inflammation, signs and symptoms of infection present in the 2 weeks prior to first study drug use requiring oral or intravenous antibiotic therapy, except for prophylactic antibiotics;
  12. history of interstitial lung disease, noninfectious pneumonia, pulmonary fibrosis, or other uncontrolled acute lung disease;
  13. Patients with active tuberculosis infection detected by history or CT examination, or patients with a history of active tuberculosis infection within 1 year prior to enrollment, or patients with a history of active tuberculosis infection more than 1 year before that have not been formally treated;
  14. Participants had active (HBV DNA ≥ 2000 IU/mL or 104 copies/mL), (positive for hepatitis C antibodies and HCV-RNA above the lower limit of the assay);
  15. Laboratory values of sodium, potassium, and calcium greater than grade 1 were abnormal in the first 2 weeks of randomization and could not be improved after treatment;
  16. known allergy to macromolecular protein preparations, or to any carrelizul component, or allergy, or to paclitaxel or cisplatin or any of the ingredients used in their preparations;
  17. Any other diagnosed prior to the first use of the study drug, except for malignancies with a low risk of and death (5-year survival >90%), such as adequately treated basal cell or squamous cell skin cancer or cervical carcinoma in situ;
  18. pregnant or lactating women; participants of who are unwilling or unable to use effective ;
  19. According to the investigator's judgment, the subject has other factors that may cause him to be forced to terminate the study halfway, such as other serious diseases (including psychiatric diseases) that require combined treatment, recent combination with other serious diseases (such as myocardial infarction, cerebrovascular accident) considering a high risk of recurrence, serious abnormal laboratory test values, family or social factors, which may affect the safety of subjects or the collection of trial data
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental group: carrelizumab in combination with concurrent chemoradiotherapy

    Study drugs were administered intravenously on the first day of each cycle. Administered sequentially: carrelizumab, 200mg/time, paclitaxel, 50mg/m2, cisplatin, 25mg/m2, chemotherapy once a week, a total of 5 doses, carrelizumab every three weeks until PD or intolerable, up to 2 years, simultaneous radiotherapy at the first dose, the total dose of radiotherapy is 50.4Gy, completed in 28 divided doses, 1.8Gy each time, 5 times a week.

    Drug: Carrelizumab · Drug: Paclitaxel injection · Drug: Cisplatin · Radiation: Concurrent chemoradiotherapy

  • Placebo comparator
    Control group: placebo-resistant in combination with chemoradiotherapy

    Placebo: 200 mg intravenously given with Q3W until PD or intolerable, carrelizumab/placebo for up to 2 years. Paclitaxel: 50mg/m2, iv, D1, 8, 15, 22, 29, once a week, a total of 5 times. cisplatin: 25mg/m2,iv, D1, 8, 15, 22, 29, once a week, a total of 5 doses. Radiotherapy: total dose of 50.4 Gy, completed in 28 divided doses of 1.8 Gy each time, 5 times a week.

    Drug: Paclitaxel injection · Drug: Cisplatin · Radiation: Concurrent chemoradiotherapy

Interventions

  • DrugCamrelizumabStudies of CamrelizumabCamrelizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    200 mg/time, iv, Q3W

    Also known as: Erica

  • DrugPaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    50mg/m2,iv, D1, 8, 15, 22, 29, once a week, a total of 5 times

    Also known as: chemotherapy

  • 25mg/m2,iv, D1、8、15、22、29,once a week, a total of 5 times

    Also known as: chemotherapy

  • RadiationConcurrent chemoradiotherapy

    Radiotherapy was given simultaneously at the time of the first dose, and the total dose of radiotherapy was 50.4 Gy, which was completed in 28 divided doses of 1.8 Gy each time, 5 times a week.

    Also known as: Radiotherapy

06

What researchers measure

Primary outcomes

  1. PFS evaluated by IRC

    IRC stands for Independent Review Committee Assessment,Progression-free disease as assessed by an independent review committee Progression-free survival refers to the time from randomization to the first occurrence of disease progression or death from any cause

    Time frame: up to 2 years

Secondary outcomes

  1. OS Overall Survival

    Overall survival was measured from the initiation of chemotherapy to the date of the last follow-up or death.

    Time frame: up to 2 years

  2. ORR

    Proportion of patients with reduction in tumor burden of a predefined amount, including complete remission and partial remission

    Time frame: through study completion, an average of 18 month

  3. Progression-free survival evaluated by Researchers

    The PFS was calculated from the initiation of chemotherapy to the date of disease progression or death.

    Time frame: up to 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Jul 2025, 36 months after the start.

Of 37 interventional studies with no phase under Esophageal Squamous Cell Carcinoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2023
First posted
Sep 21, 2023
StartActual
Jul 30, 2022
Primary completionEst.
Jul 30, 2025
CompletionEst.
Jul 30, 2028
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06048926
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Jul 30, 2022
Primary completion
Jul 30, 2025 (estimated)
Completion
Jul 30, 2028 (estimated)
Last update
Sep 21, 2023

Study contacts

Xiaolin MM GE
study director · The First Affiliated Hospital with Nanjing Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camrelizumab

Start the discussion